News
LNTH
63.50
-3.83%
-2.53
IBD Stock Of The Day: After A 121% Run, What Does Lantheus Have Left?
Lantheus Holdings is the IBD Stock Of The Day as LNTH stock consolidates following a monstrous run-up that began in February.
Investor's Business Daily · 2d ago
Is Lantheus (LNTH) Stock Outpacing Its Medical Peers This Year?
Here is how Lantheus Holdings (LNTH) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
Zacks · 4d ago
Tenet Healthcare (THC) Unit Ties Up to Boost Urology Services
Tenet Healthcare's (THC) unit, USPI, signs a joint venture partnership with UUG to acquire ownership interests in the latter's 22 ambulatory surgery centers and concurrently assuring to develop these centers.
Zacks · 06/22 23:50
I've Got an Options Bandage for a Sick Economy
Let's see why this diagnostics and therapeutic imaging company might be just what the doctor ordered in an ailing economy.
TheStreet.com · 06/19 11:30
While shareholders of Lantheus Holdings (NASDAQ:LNTH) are in the black over 5 years, those who bought a week ago aren't so fortunate
The Lantheus Holdings, Inc. ( NASDAQ:LNTH ) share price has had a bad week, falling 14%. But that doesn't undermine the...
Simply Wall St. · 06/15 13:13
Paul Blanchfield promoted as COO at Lantheus Holdings
Paul Blanchfield has been promoted to Chief Operating Officer at Lantheus Holdings (NASDAQ:LNTH). Blanchfield joined the company as Chief Commercial Officer in Jan. 2020. In the new role, he will
Seekingalpha · 06/15 13:08
Lantheus Holdings (LNTH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Lantheus Holdings (LNTH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the sto...
Zacks · 06/13 13:55
Lantheus's Imaging Agent Can Assess PD-L1 Expression for Immunotherapy In Cancer Patients
Benzinga · 06/13 12:34
BRIEF-Lantheus Highlights Preliminary Study Results Demonstrating Potential Of NM-01, A Novel Technetium-99M Spect/Ct Imaging Agent, To Assess PD-L1 Expression For Immunotherapy In Cancer
reuters.com · 06/13 12:29
BRIEF-Lantheus' Pylarify AI Platform Demonstrates Higher Efficiency For Assessment Of Psma Imaging In Prostate Cancer
reuters.com · 06/13 12:23
Lantheus Highlights Preliminary Study Results Demonstrating Potential Of NM-01 To Assess PD-L1 Expression For Immunotherapy In Cancer
Lantheus Holdings, Inc. (“the Company”) (NASDAQ:LNTH) is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find,
Benzinga · 06/13 12:09
Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer
Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual MeetingNORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving patient outcom...
GlobeNewswire · 06/13 12:00
Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer
Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in VancouverNORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving p...
GlobeNewswire · 06/13 11:45
How Much Upside is Left in Lantheus Holdings (LNTH)? Wall Street Analysts Think 27%
The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might ...
Zacks · 06/09 13:55
SVB Securities Assumes Lantheus Holdings at Outperform with $100 Price Target
MT Newswires · 06/06 08:38
What Makes Lantheus Holdings (LNTH) a Good Fit for "Trend Investing"
Lantheus Holdings (LNTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks · 06/03 12:50
Lantheus to Present at the Jefferies Healthcare Conference
NORTH BILLERICA, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intellig...
GlobeNewswire · 06/02 12:30
Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intellige...
GlobeNewswire · 05/26 12:00
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
Style Box ETF report for FYX
Zacks · 05/23 10:20
Wall Street Analysts Predict a 44% Upside in Lantheus Holdings (LNTH): Here's What You Should Know
The consensus price target hints at a 44.2% upside potential for Lantheus Holdings (LNTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witne...
Zacks · 05/20 13:55
More
Webull provides a variety of real-time LNTH stock news. You can receive the latest news about Lantheus Holding through multiple platforms. This information may help you make smarter investment decisions.
About LNTH
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. The Company classify its commercial products in three categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Its products in its precision diagnostics category includes DEFINITY, TechneLite, NEUROLITE, Xenon-133, Cardiolite, Gallium-67 and Thallium-201. Its products in its radiopharmaceutical oncology category includes PYLARIFY and AZEDRA. Its products in its strategic partnerships and other revenue product category includes RELISTOR, Automated Bone Scan Index (aBSI) and PYLARIFY AI. In addition to its commercial products and strategic partnerships with third parties, it also has ongoing clinical development programs, such as 1095 and LMI 1195. Its products are sold in both the United States and internationally.